Menu
Live
Market Overview
Live indices, gainers & losers
Market Pulse
AI-curated live updates
Market Movers
Top gainers & losers by cap
Market Signals
Value, momentum & analyst signals
Smart Money
Insider & congress trades
Hedge Funds
What 63 elite funds bought & sold
52-Week Highs
Stocks breaking out to new highs
52-Week Lows
Beaten-down stocks near support
High Beta
Stocks that move more than the market
Earnings Calendar
Upcoming earnings dates
Daily
Research
Invest
LIVE
Terns Pharmaceuticals, Inc.
TERN
NASDAQ·Healthcare·Biotechnology·Mkt cap $4.8B
$52.95
▼ -0.03%
View full research view
Our plain-language verdict, the thesis, risk factors, and what is changing about the business.
View research view52-Week Range
$2.66 - $53.19
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 1220.5% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
3 reasons
- Proprietary liver-distributed drug candidates with enhanced metabolic stability and reduced systemic side effects
- Diversified pipeline targeting multiple biological pathways (FXR, VAP-1, THR-β, GLP-1) for NASH and metabolic diseases
- Oral formulation approach for GLP-1 agonist (TERN-601) offering potential advantages over injectable competitors
Bear Case
1 risk
- Low volatility (beta -0.4).
Growth
Revenue decline expected
Expanding NASH market with no FDA-approved treatments and estimated patient population exceeding 16 million in the US
Value
Deep value opportunity - significant discount to Biotech & Therapeutics peers
Momentum
Strong
+13.8% over 3m
Quality
Loss-making
Mixed fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying TERN right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: May 6, 2026
Earnings recap unavailable for this period.
EPS surprise · last 4Q
Q4 25
-$0.24
Q3 25
-$0.27
Q2 25
-$0.26
Q1 25
-$0.26
Next: May 6, 2026
Revenue trend · last 8Q
—
—
—
—
—
—
—
—
Q1 24
Q2 24
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
$0
$0
$0
$0
$0
$0
$0
$0
Margins · last 8Q
No margin history available.
Wall Street consensus
7 analysts · 14% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
14%
Hold
86%
Sell
0%
Median Price Target
—
Latest: Oppenheimer · Apr 27, 2026